Vasgene Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1998-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://vasgene.com
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Phase 2
Recruiting
- Conditions
- Muscle-Invasive Bladder CarcinomaMetastatic Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 700
- Registration Number
- NCT06493552
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma
Phase 2
Recruiting
- Conditions
- Metastatic Urothelial Carcinoma
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 38
- Registration Number
- NCT04486781
- Locations
- 🇺🇸
Sarcoma Oncology Center, Santa Monica, California, United States
A Study of sEphB4-HSA in Kaposi Sarcoma
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Vasgene Therapeutics, Inc
- Target Recruit Count
- 65
- Registration Number
- NCT03993106
- Locations
- 🇺🇸
CAN (Community AIDS Network) Community Health, Sarasota, Florida, United States
🇺🇸UT Southwestern Medical Center, Dallas, Texas, United States
🇺🇸AIDS Healthcare Foundation, Beverly Hills, California, United States
© Copyright 2025. All Rights Reserved by MedPath